Downstream Process Development for Lentiviral Vectors with Adherent Cell Culture Production

Scroll Down

Lentiviral vectors (LVV) are commonly used as an efficient and safe tool to deliver a transgene into dividing and nondividing cells, enabling long-term gene expression.

Production methods must be capable of making large quantities of high-quality functional LVV in an efficient and cost-effective way, but most current cGMP LVV production processes lack the use of sterile filter due to the low stability of lentiviral vectors. The result of which is depletion of precious final vector product on microbiological safety testing or requirement of multiple GMP
batches.

In this fact sheet, Genezen evaluates two different commercially available sterile filters and two different buffer compositions that can be incorporated into the process of LVV production. Our aim was to establish a scalable, fast and robust downstream processing with a sterile filter to maximize final recovery of lentiviral vectors.

Download our ‘Downstream process development for lentiviral vectors’ fact sheet by completing the form on the right.

You may also be interested in...

Genezen appoints Chief Commercial Officer to…

  Genezen, a cell and gene therapy Contract Development and Manufacturing...

Read more

Stable cell lines vs transient transfection…

The aim of upstream processing in viral vector development and manufacturing...

Read more

Genezen delivers next phase of cGMP…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more

Genezen, Monon Bioventures, and Purdue University…

Glioblastoma is one of the most aggressive types of cancer, affecting...

Read more